Stone Pharmaceutical Group: Revenue of 12.59 billion yuan in the first half of 2020, up 12.6% YoY

Introduction: Shareholders' profit attributable increased by 23.2% to RMB2,314 million.
26, 2020, Stone Pharmaceutical Group announced its interim results for the year ended June 30, 2020.
the review period, the Group recorded sales revenue of RMB12.59 billion, up 12.6% YoY, while shareholders should account for RMB2.314 billion in profit, up 23.2% YoY.
earnings per share were RMB30.97.
board of directors announced an interim dividend of 6 Hong Kong cents per share and recommended the issuance of red shares.
, the Group has been actively promoting online and flexible sales strategies to mitigate the impact of the new crown outbreak on sales.
same time, through professional academic promotion, hospital development, market sinking, clinical application scope expansion, professional sales force expansion and other work, so that the focus of pharmaceutical products have maintained rapid growth.
new products in the 2000s bring new sales revenue contributions and make the product structure of the pharmaceutical business more balanced.
the first half of 2020, the pharmaceutical business recorded sales revenue of RMB10,231 million, an increase of 16.7% over the same period last year.
the fastest growth were in cardiovascular diseases, respiratory diseases and anti-tumor products, with growth of 54.0%, 50.4% and 44.4%, respectively.
has also made good progress in research and development: i) obtained 9 domestic drug registration approvals, including Devasalban tablets, Menziestetablets, Menziestechewing tablets, mendonine birdine injections, injection boron tyzo Rice, Celexib capsules, acaposulose tablets, hydrochloric acid macaque tablets and hydrochloric acid loxitin intestinal capsules; ii) obtained 1 U.S. AND batch (Omega-3-ethyl acid 90 softgels); iii) submitted hydrochloric acid mitol Applications for the listing and acceptance of new Chinese drugs for liposome injections (new preparations); iv) completion of the briditation trial case of the innovative drug Duvelisib in China, and v) acquisition of 5 clinical approvals in China, including Ylithycom lipid injections, injections of dositan SYHA1805 tablets, SYHA1815 tablets and recombinant anti-IgE monoclonal antibodies for injection, ALMB-0168 clinical approval in Australia and Y150 (CD38/ CD3 dual specific antibodies) in clinical batches in the United States.
firmly believes in the importance of investing resources in research and development.
research and development expenses amounted to RMB1,452 million (included in the income statement), an increase of 54.2% YoY, accounting for about 14.2% of the revenue of the pharmaceutical business.
is currently in the research project more than 300 items, including small molecule innovation drugs more than 40 items, large molecule innovation drugs more than 50 items, new preparations more than 20 items, mainly focused on tumor, autoimmune, mental nerve, digestion and metabolism, cardiovascular system and anti-infection treatment field.
Currently, 25 drugs are in the registration review phase, 42 products are undergoing clinical trials (including 31 innovative drugs and 11 new preparations), 9 products are undergoing bioethic trials, and 7 products are pending clinical approval (6 domestic and 1 United States).
In the next three years, the Group is expected to list more than 50 new products, of which it is expected that the market space of more than 1 billion yuan of heavy-weight varieties will be no less than 15, can strongly support the Group's future high-quality growth.
.